No Data
No Data
NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sales Of NRX-100 (IV Ketamine) Pending FDA Approval,...
NRx Pharmaceuticals Outlines Potential Paths To Revenue And Profitability In 2025; New Shareholder Update Highlights Potential 2024 Revenue From HOPE Therapeutics-Branded Clinics, 2025 Revenue From Sa
Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update Letter PR Newswire RADNOR, Pa., July 1, 2024 -- Potential paths to revenue and profitability in 2025 RADNOR, Pa., July 1, 2024 /PR
Express News | NRX Pharmaceuticals Inc: Nda for NRX-100 in Advanced Preparation for Submission in 2024, Potential Revenue in 2025
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) to Proceed With Two New Drug Applications in 2024; NRX-101 Has Been Returned to the Company for Filing
Express News | NRX Pharmaceuticals Inc - Agreement Provided for the Joint Development, Supply, Marketing, Commercialization and License to Alvogen of NRX-101
Express News | NRX Pharmaceuticals Inc - Continues to Finalize a New Drug Approval Application for Intravenous Ketamine (NRX-100), to Be Submitted This Year